Lung Adjuvant

ALLIANCE A212102 **AT MBMC ONLY** ** As of 2/22/23 participants without a cancer diagnosis will be Temporarily Closed to Enrollment** **White female participants under (<) age 60 without a cancer diagnosis will temporarily be suspended on 12/1/22 3:30 cst**

Blinded Reference Set For Multicancer Early Detection Blood Tests

---

URCC 19075 **MBMC ONLY** (Temporarily Closed to Enrollment)

Multi-Center Randomized Controlled Phase II Trial of Exercise to Treat Chemotherapy-Induced Peripheral Neuropathy (CIPN)

---

URCC-21038

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

---

A081801

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---

ECOG E4512 (NCT02201992) **SUSPENDED** – Must have Consented to ALCHEMIST A151216 Trial

A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

---

A151216 (NCT02194738) ALCHEMIST

Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

---